Oral Proteins And Peptides Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Oral Proteins And Peptides Market Trends and Insights

GLP-1 Oralization Momentum and Obesity Pill Launches Expand Addressable Market and Adherence

Eli Lilly’s Foundayo (orforglipron) won FDA approval in April 2026, and Novo Nordisk’s 25 mg oral semaglutide tablet reached U.S. pharmacies in January 2026, creating the first obesity-labeled peptide tablets to hit commercial scale^{[1]Centers for Medicare & Medicaid Services, “Medicare GLP-1 Bridge,” cms.gov}. The Medicare GLP-1 Bridge demonstration, effective July 2026, reimburses both products at a USD 245 net monthly price with a USD 50 out-of-pocket cost, underscoring payer readiness to fund oral peptides that improve persistence. A 78,297-patient U.S. claims analysis found that oral semaglutide achieved 65.1% high adherence at 12 months versus 38.8% for injectables. However, an Italian observational study showed that 18-month persistence fell to 46.0% owing to gastrointestinal intolerance. The data suggest the oral proteins and peptides market will benefit when second-generation tablets reduce fasting windows and nausea rates. 

Patient Preference and Adherence Shift from Injections to Oral Macromolecules in Chronic Diseases

High refill adherence correlates with lower disease activity across multiple chronic illnesses, and ease of administration drives that adherence. Real-world studies in inflammatory bowel disease linked 80% medication possession to a 70% fall in active-disease odds. Emerging oral peptides must therefore balance convenience with tolerability; strict “water-only” fasting rules and dose-related dyspepsia threaten persistence. Phase 2 and Phase 3 assets such as Structure Therapeutics’ GSBR-1290 and Hansoh Pharma’s HS-10535 aim to cut fasting windows below 10 minutes and reduce emetogenicity, suggesting future crowd-out pressure on weekly injectables.

Regulatory Tailwinds for Oral Peptides

The FDA’s December 2023 guidance spells out immunogenicity testing, hepatic-impairment protocols, and labeling specifics for peptide drugs, trimming filing risks^{[2]U.S. Food and Drug Administration, “Clinical Pharmacology Considerations for Peptide Drug Products,” fda.gov}. Japan’s PMDA followed with a new-modalities webpage in October 2025, and Europe is harmonizing bioequivalence rules for excipient-rich tablets. Most notably, the Medicare GLP-1 Bridge demonstration reframes oral peptides as budget-impact tools rather than specialty outliers, a precedent likely to shape private-plan formularies.

Next-Generation Ingestible Devices Unlock Systemic Delivery of Large Proteins

Device-mediated capsules such as the RaniPill inflate a balloon in the jejunum and deliver microneedle injections that produced 84% bioavailability for an ustekinumab biosimilar in a Phase 1 trial^{[3]Rani Therapeutics, “Investor Presentation Q1 2026,” ranitherapeutics.com}. A USD 1.085 billion licensing accord with Chugai in 2025 validated the economics of this approach. Biora’s BioJet and NaviCap platforms show similar promise but must address device reliability and cost-of-goods before wide payer adoption.

Very Low and Variable Oral Bioavailability Drives High API Loads and Cost of Goods

Classic oral peptides rarely exceed 1% absorption, forcing 10–100× injectable doses and inflating both cost and gastrointestinal side-effects. Oral semaglutide requires 14 mg to match a 1 mg injection and still posts 50-60% coefficient-of-variation in exposure. Variability undermines the oral proteins and peptides market size economics.

Complex CMC and Stringent Regulatory Evidence for Enhancer/Device Safety

Every enhancer adds analytical, impurity, and stability tests; each ingestible device must clear drug and device rules plus human-factor engineering reviews. PMDA’s 2025 bioequivalence guidance excludes device-mediated products, pushing Japan launches past 2030 unless new frameworks emerge.

Segment Analysis

By Molecule Class: Peptides Lead, Proteins Accelerate via Device Platforms

Peptides held 78.31% of the oral proteins and peptides market in 2025 thanks to entrenched GLP-1 and GC-C franchises. The oral proteins and peptides market size for proteins and enzymes is projected to expand at 16.32% CAGR as ingestible injectors sidestep gut-wall barriers. Ironwood’s LINZESS peptide reported USD 272.5 million Q1 2026 revenue, up 97% year over year, illustrating peptide resilience. In parallel, RaniPill achieved 84% bioavailability for ustekinumab biosimilar, validating protein delivery viability. The segment’s long-run upside hinges on scaling device manufacturing and proving repeat-dose intestinal safety. 

Second-generation enzyme formulations also reinforce protein upside. Updated CREON and Pertzye labels now cite coefficients of fat absorption above 83%, providing clear efficacy endpoints that justify premium reimbursement. Still, proteins face steep cost-of-goods when classical oral formulations demand gram-level API loads, keeping device platforms central to growth.

By Drug Class: GLP-1 Dominance Meets Pancreatic Enzyme Acceleration

GLP-1 receptor agonists commanded 48.86% of oral proteins and peptides market share in 2025 on the back of Rybelsus and Wegovy tablets. The oral proteins and peptides market size linked to pancreatic enzymes, though smaller today, is forecast to advance 16.92% CAGR, reflecting underdiagnosis correction in EPI. CMS now reimburses Foundayo and Wegovy tablets for both diabetes and weight management, accelerating GLP-1 uptake. Yet gastrointestinal adverse events remain a leading discontinuation trigger, tilting development toward better-tolerated macrocyclics and dual-agonists. 

GC-C agonists, led by LINZESS, posted a 97% top-line jump in Q1 2026 and provide a blueprint for segment durability. Somatostatin analogs and vasopressin derivatives remain niche, restrained by exposure variability that regulators struggle to reconcile with tight therapeutic windows.

By Indication: Type 2 Diabetes Leadership, EPI Fastest Growth

Type 2 diabetes generated 54.6% of 2025 revenue, but EPI is set to grow fastest at 16.67% CAGR through 2031. Obesity, now a distinct indication with Foundayo and Wegovy tablets, represents an expanding adjacency that converts injection-averse populations into oral peptide candidates. Meanwhile, IBS-C and chronic idiopathic constipation maintain mid-teen growth fueled by GC-C agonist adoption. 

Label revisions for CREON and Pertzye that document fat-absorption improvements support pay-for-performance contracting, driving EPI therapy uptake. Conversely, acromegaly remains a limited market until variability challenges for oral octreotide are overcome.

Geography Analysis

North America retained 45.75% of 2025 revenue, bolstered by payer initiatives like the Medicare GLP-1 Bridge and clear FDA peptide guidance. The region also hosts most ingestible-device clinical sites, positioning it to capture early protein-delivery upside. Yet real-world adherence gaps driven by gastrointestinal side-effects cap long-term share gains. 

Europe benefits from centralized health-technology assessments that welcome oral options when they lower nurse-administered costs. EMA alignment on peptide bioequivalence lowers filing risk, encouraging biosimilar entrants that could compress price points. 

Asia-Pacific is projected to record a 16.12% CAGR to 2031, supported by China’s regulatory openness to incretin innovation and Japan’s modality-specific PMDA guidance. Local manufacturing pacts, such as AstraZeneca’s USD 1.2 billion CSPC agreement, aim to regionalize supply chains, cutting tariffs and shipping cost for high-dose tablets. 

South America and the Middle East & Africa remain nascent, constrained by reimbursement hurdles and limited cold-chain infrastructure. Nonetheless, rising obesity prevalence and tele-pharmacy adoption point toward future opportunities once cheaper generic peptides arrive.